In Vitro Assay Service of CRS

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Based on the unrivaled expertise and experience in immunotherapy discovery and development, Creative Biolabs independently has developed a novel in vitro assay service of CRS for global clients to speed up the development of immunotherapy projects.

The Basis of In Vitro Assay Service of CRS

In Vitro Assay Service of CRS In recent years, immune-oncology therapies such as checkpoint inhibitors, bi-specific antibodies, and CAR-T cell therapies have brought a great promise for cancer therapy. However, they can have very severe adverse effects such as cytokine release syndrome (CRS). Currently, various in vitro assay formats can be considered when evaluating the potential for cytokine release and cytotoxicity. Despite the challenges of interpreting cytokine release assay (CRA) data, cytokine release assessment has become a growing useful tool for predicting the safety of immunotherapies. The positive results of cytokine level and cytotoxicity in vitro can provide the theoretical basis for determining the starting dose of therapies. Therefore, the development of a well-established assay or one that can reliably predict the potential of immunotherapy to initiate cytokine release syndrome is still urgently needed.

CBL's In Vitro Assay Service of CRS

In Vitro Assay Service of CRS

Creative Biolabs can provide both in vitro cytokine release assay service and in vitro cytotoxicity analysis service. What is more, the diversity of modalities of action of specific drugs in induction cytokine release may need the availability of adaptive or flexible in vitro assay platforms to identify potential clinical risk for specific therapeutic candidates. Creative Biolabs will optimize the experimental conditions as much as possible according to the requirements of your project and provide our clients with appropriate customized services.

Working with Creative Biolabs

With profound expertise and state-of-the-art technology platforms, we are committed to providing tailored services to each project to ensure that the objectives are met or exceeded. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.

References

Grimaldi, C., et al. Cytokine release: workshop proceedings on the state-of-the-science, current challenges, and future directions. Cytokine, (2016): 85, 101-108.
Draheim, Kyle, et al. An in vivo model to evaluate donor-dependent cytokine release in response to single-agent or combination immune-oncology therapies. (2020): 3114-3114.
Shimabukuro-Vornhagen, A., et al. Cytokine release syndrome. Journal for immunotherapy of cancer, (2018): 6(1), 1-14.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION